BioSpace News Archive

Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases, today announced second quarter 2022 results and provided a business update.

ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reported financial results for the three and six months ended June 30, 2022, and provided a business update.

Sonnet BioTherapeutics Holdings, Inc., a biopharmaceutical company developing innovative targeted biologic drugs, announced its financial results for the three months ended June 30, 2022 and provided a business update.

Dermata Therapeutics, Inc., a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, highlighted recent corporate progress and reported financial results for the quarter ended June 30, 2022.

CinCor Pharma, Inc. announced the closing of its previously announced upsized underwritten public offering consisting of an aggregate of 8,625,000 shares of common stock and pre-funded warrants.

Ra Medical Systems, Inc. (NYSE American: RMED) (“Ra Medical” or the “Company”) reports financial results for the three and six months ended June 30, 2022 and provides a business update.

Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”, the “Company”), today provided a business update for the Company and presented preliminary financial results for the three and six months ended June 30, 2022.

Biotricity Inc., a medical diagnostic and consumer healthcare technology company, announced its financial results for its fiscal 2023 first quarter ended June 30, 2022.

Emmaus Life Sciences, Inc. (OTCQX: EMMA), today reported financial results for the three and six months ended June 30, 2022 and provided a business update.

ProMIS Neurosciences, Inc. (TSX: PMN) (Nasdaq: PMN) (“ProMIS” or the “Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers, implicated in the development of neurodegenerative diseases, today announced its operational and financial results for the three months ended June 30, 2022.